- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03978780
기립자 Spinae 블록 대 위약 블록 연구
외래 유방암 수술에서 기립자 척추 블록 대 가짜 블록에 따른 회복 점수의 품질: 무작위 통제 시험
Regional anaesthesia combined with general anaesthesia has become common in the perioperative management of breast cancer surgery patients. Regional techniques have been recognised to provide excellent post-operative analgesia. It enhances multi-modal analgesia regimes while being opioid sparing, reducing incidence of post-operative nausea and vomiting and allowing earlier mobilisation/discharge and improving treatment success. Therefore identifying the correct regional anaesthetic technique for this group of patients is important in providing optimum peri-operative care.
연구 개요
상세 설명
The ultrasound-guided erector spinae plane (ESP) block has been recently described for the successful management of thoracic neuropathic pain. The erector spinae muscle is formed by the spinalis, longissimus thoracis, and iliocostalis muscles that run vertically in the back. The ESP block is performed by depositing the local anaesthetic in the fascial plane, deep to the erector spinae muscle, at the tip of the transverse process of the vertebra. Indirect access to the paravertebral space is gained providing analgesia without the risk of needle injury to structures in close proximity. Cadaveric studies have shown both ventral and dorsal rami of thoracic spinal nerves are affected when local anaesthetic is injected deep to the erector spinae muscle. The erector spinae muscle extends along the thoracolumbar spine allowing extensive cranio-caudal spread. The ventral ramus (intercostal nerve) is divided into the anterior and lateral branches. Its terminal branches provide the sensory innervation of the entire anterolateral wall. The dorsal ramus is divided into 2 terminal branches and it gives the sensory innervation to the posterior wall. Anterior spread of the local anaesthetic to the paravertebral space through the costotransverse foramina and the intertransverse complex provides both visceral and somatic analgesia.
While recent evidence supports statistically significant reductions in pain and opioid consumption among patients who receive an ESP block compared to systemic analgesia alone, the clinical significance of these differences are questionable the effect of ESP block on the patients' quality of recovery following ambulatory breast cancer surgery remains unclear.
Therefore, our objective is to determine whether or not the addition of an ESP block provides both superior analgesia and quality of recovery in patients undergoing ambulatory breast cancer surgery compared to systemic analgesia alone. We hypothesis that patients who received a preoperative ESP block will afford superior postoperative analgesia and improve the quality of recovery over the first 24 hours following surgery compared to those who receive a sham block for their ambulatory breast cancer surgery.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5S 1B2
- Women's College Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- ASA classification: I-III
- BMI < 35 kg/m2
- Day surgery procedure
Exclusion Criteria:
- Prior ipsilateral breast surgery, excluding lumpectomy
- Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
- Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases
- Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe / poorly controlled asthma)
- Contraindication to regional anaesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)
- Patient refusal
- Chronic pain disorder
- Chronic opioid use (≥30 mg oxycodone / day)
- Contraindication (or allergy) to a component of multi-modal analgesia protocol
- Allergy to amide local anaesthetics used in nerve blocks
- Contraindications to any of the components of the standardized general anaesthesia
- Significant psychiatric disorder that would preclude objective study assessment
- Pregnancy/ women with nursing infants
- Unable to provide informed consent
- Unable to speak and read English
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Control Group
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure. |
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure. |
|
실험적: Erector spinae plane (ESP) block group
Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed. |
80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Acute postoperative pain at rest
기간: 24 hours postoperatively
|
Following breast surgery, measured as an area under the curve (AUC) of rest pain scores VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable |
24 hours postoperatively
|
|
Quality of postoperative recovery (QoR 15)
기간: 24 hours post-surgery
|
Quality of recovery at 24 hours: questionnaire (0-10, where 0 = none of the time [poor] and 10 = all of the time [excellent]) |
24 hours post-surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Postoperative pain scores
기간: 0, 6, 12, 18, 24 and 48 hours post-operatively
|
VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable |
0, 6, 12, 18, 24 and 48 hours post-operatively
|
|
Intraoperative opioid consumption
기간: During the procedure
|
Cumulative oral morphine equivalent after surgery |
During the procedure
|
|
Postoperative opioid consumption
기간: 12,24,48 hours, 7 days postoperative
|
Cumulative oral morphine equivalent after surgery |
12,24,48 hours, 7 days postoperative
|
|
Duration of phase I (PACU) and phase II (surgical day care, SDC) stay
기간: From end of surgical procedure to 24 hours after surgery
|
How fast is the recovery is-expressed in minutes |
From end of surgical procedure to 24 hours after surgery
|
|
Opioid-related side effects
기간: End of surgical procedure to 48 hours after surgery
|
Risk of opioid-related side effects(nausea, vomiting, pruritis) |
End of surgical procedure to 48 hours after surgery
|
|
Persistent post surgical pain DN4 screening tool
기간: 3 months post operatively
|
Satisfaction with pain management. Is prescribed pain medication enough? |
3 months post operatively
|
|
Block-related complications
기간: End of surgical procedure to 48 hours after surgery
|
bruising at injection site, numbness over lateral chest, weakness of shoulder or arm, pain/swelling at injection site |
End of surgical procedure to 48 hours after surgery
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Richard Brull, MD,FRCPC, Women's College Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 2021-0048-B
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .